American Journal of Cardiology最新文献_第4页

Decreases in Left Atrial Strain With Mavacamten Therapy and Associations With Atrial Fibrillation. 马伐卡坦治疗降低左心房劳损与房颤的关系

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-29 DOI: 10.1016/j.amjcard.2026.09.023

Myra Lewontin, Yaqub Betz, Kenneth C Bilchick, Jonathan R Lindner, Christopher M Kramer, James P MacNamara, Karen McClean, Matthew Thomas, Allison Perry, Kaitlyn Amos, Anna Parrish, Michael Ayers

{"title":"Decreases in Left Atrial Strain With Mavacamten Therapy and Associations With Atrial Fibrillation.","authors":"Myra Lewontin, Yaqub Betz, Kenneth C Bilchick, Jonathan R Lindner, Christopher M Kramer, James P MacNamara, Karen McClean, Matthew Thomas, Allison Perry, Kaitlyn Amos, Anna Parrish, Michael Ayers","doi":"10.1016/j.amjcard.2026.09.023","DOIUrl":"10.1016/j.amjcard.2026.09.023","url":null,"abstract":"In obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor mavacamten improves left ventricular outflow tract obstruction and functional capacity. Symptoms and exertional capacity in obstructive hypertrophic cardiomyopathy are also influenced by left atrial function, commonly assessed by left atrial strain (LAS). Current data regarding effects of cardiac myosin inhibitors on LAS are mixed. To assess changes in LAS in patients on mavacamten and correlate strain patterns to atrial fibrillation (AF) development. Serial echocardiograms were obtained following mavacamten initiation. We remeasured 2-dimensional and Doppler-derived measurements and obtained strain measurements. We examined temporal changes in LAS and related parameters, including those determining atrial preload and afterload, along with ventricular changes affecting atrial function. We included 434 echocardiograms from 65 patients. After 24 weeks of therapy, left ventricular outflow tract gradient, global longitudinal strain, and left ventricular ejection fraction all decreased. Left atrial volume index (p <0.001), mitral regurgitation severity (p = 0.01), and E/e' velocities (p = 0.01) also decreased. All 3 components of LAS worsened (p <0.001). Seven patients with baseline AF had recurrences, and 4 others had new-onset AF. LAS predicted AF as a time-dependent variable. Decreases in LAS seen with mavacamten may be downstream effects of alterations to other hemodynamic parameters, a decline in atrial function, or a combination thereof. LAS reductions may therefore represent harmful effects on the left atrium or neutral byproducts of other changes, although the association between LAS and AF is notable and may highlight prognostic implications of strain measurements in this population.","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing Risk and Reward for Chronic Total Occlusion PCI. 优化慢性全闭塞PCI的风险和回报。

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-29 DOI: 10.1016/j.amjcard.2026.09.027

Craig R Narins

引用次数: 0

Effect of Intracoronary Adenosine on No-Reflow in Patients With Acute ST-Elevation Myocardial Infarction Undergoing Primary PCI: A Randomized Controlled Trial. 冠状动脉内腺苷对急性st段抬高型心肌梗死行首次PCI患者无再流的影响：一项随机对照试验。

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-26 DOI: 10.1016/j.amjcard.2026.09.017

Ahmed Saad, Oluwakorede Akele, Vaishvik Patel, Ahmed Al Ghazaway

{"title":"Effect of Intracoronary Adenosine on No-Reflow in Patients With Acute ST-Elevation Myocardial Infarction Undergoing Primary PCI: A Randomized Controlled Trial.","authors":"Ahmed Saad, Oluwakorede Akele, Vaishvik Patel, Ahmed Al Ghazaway","doi":"10.1016/j.amjcard.2026.09.017","DOIUrl":"10.1016/j.amjcard.2026.09.017","url":null,"abstract":"No-reflow complicates 7% to 25% of primary percutaneous coronary interventions (PCI) for ST-elevation myocardial infarction (STEMI) and is associated with adverse outcomes. This trial evaluated whether intracoronary adenosine prevents no-reflow and improves left ventricular (LV) function. This single-center randomized controlled trial enrolled 200 STEMI patients undergoing primary PCI. Patients received either intracoronary adenosine (1 to 2 mg, n = 100) or standard care (n = 100) after achieving Thrombolysis in Myocardial Infarction (TIMI) 1 flow. Primary endpoints were postprocedural TIMI flow grade and myocardial blush grade. Secondary endpoints included LV ejection fraction and dimensions. Adenosine significantly reduced the incidence (33% vs 60%, p < 0.001) and improved TIMI III flow (86% vs 49%, p < 0.001) and myocardial blush grade III (68% vs 42%, p = 0.003). Post-PCI LV ejection fraction was higher in the adenosine group (42.64 ± 8.92% vs 38.40 ± 9.34%, p = 0.001) with smaller LV volumes. Intracoronary adenosine administered after establishing TIMI 1 flow significantly reduces no-reflow, improves myocardial perfusion, and preserves ventricular function in STEMI patients undergoing primary PCI. In conclusion, intracoronary adenosine administered during primary PCI was associated with reduced angiographic no-reflow, improved reperfusion markers, and more favorable early echocardiographic parameters among patients with STEMI. Given the single-center design and absence of long-term clinical outcomes, these findings should be considered preliminary and require external validation.","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Disease and Associated Risk Factors Among Transgender and Gender Diverse Individuals. 跨性别和性别多样化个体的心血管疾病及其相关危险因素

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-24 DOI: 10.1016/j.amjcard.2026.09.018

Alexandra Balshi, Hannah R Thompson, Jennifer Manne-Goehler, John P Dempsey, Yanli Zhang-James, Mary W Montgomery

{"title":"Cardiovascular Disease and Associated Risk Factors Among Transgender and Gender Diverse Individuals.","authors":"Alexandra Balshi, Hannah R Thompson, Jennifer Manne-Goehler, John P Dempsey, Yanli Zhang-James, Mary W Montgomery","doi":"10.1016/j.amjcard.2026.09.018","DOIUrl":"10.1016/j.amjcard.2026.09.018","url":null,"abstract":"Although health disparities among transgender and gender diverse (TGD) individuals are increasingly recognized, the risks of cardiovascular disease in this population remain understudied. This multicenter analysis investigates whether TGD individuals face greater risk of cardiovascular disease and associated cardiometabolic risk factors compared to cisgender individuals. Using data from a multicenter research network from 2010 to 2026, we propensity score 1:1 matched TGD and cisgender individuals by age, sex assigned at birth, race, and ethnicity. We compared matched cohorts (n = 36,052 per cohort) using risk ratios (RRs) with 95% confidence intervals (CIs). Compared to cisgender individuals, TGD individuals had greater risks of major adverse cardiovascular events (RR 1.23, 95% CI 1.11-1.35), ischemic heart disease (RR 1.29, 95% CI 1.17-1.43), acute myocardial infarction (RR 1.64, 95% CI 1.38-1.94), heart failure (RR 1.62, 95% CI 1.42-1.85), cardiomyopathy (RR 1.47, 95% CI 1.23-1.76), cardiac arrhythmias (RR 1.53, 95% CI 1.32-1.77), peripheral artery disease (RR 1.36, 95% CI 1.20-1.54), and venous thromboembolism (RR 1.36, 95% CI 1.18-1.57). TGD individuals also had greater risks of associated cardiometabolic risk factors: hypertension (RR 1.11, 95% CI 1.05-1.17), dyslipidemia (RR 1.24, 95% CI 1.19-1.29), pre-diabetes (RR 1.57, 95% CI 1.46-1.69), type II diabetes (RR 1.38, 95% CI 1.27-1.50), overweight or obesity (RR 1.35, 95% CI 1.31-1.39), tobacco use (RR 1.68, 95% CI 1.59-1.78), alcohol use disorder (RR 1.65, 95% CI 1.51-1.79), and insomnia (RR 2.36, 95% CI 2.24-2.49). TGD individuals demonstrate greater risks of numerous cardiovascular diseases and associated cardiometabolic risk factors. Additional longitudinal studies are warranted to further assess these differential risks.","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of Perioperative Major Adverse Cardiovascular Events After Bariatric Surgery. 社论：减肥手术后围手术期主要心血管不良事件的预测因素。

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-18 DOI: 10.1016/j.amjcard.2026.09.012

Sheng Kang

引用次数: 0

Coronary Atherectomy: Is There a Surgeon in the House? 冠状动脉粥样硬化切除术-有外科医生在家里吗？

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-12 DOI: 10.1016/j.amjcard.2026.09.004

Donald E Cutlip

引用次数: 0

Late Is Not Too Late, but It Is Not Free: Timing of M-TEER in Degenerative Mitral Regurgitation. 迟了不算太晚，但也不是免费的：退行性二尖瓣返流的M-TEER时间。

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-11 DOI: 10.1016/j.amjcard.2026.09.005

Andrea Panza, Giuseppe Tarantini

引用次数: 0

Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients With ST-Elevation Myocardial Infarction: Analysis From the CELEBRATE Trial. 扎仑非班对st段抬高型心肌梗死患者肌酐清除率的疗效和安全性：来自CELEBRATE试验的分析。

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-09-11 DOI: 10.1016/j.amjcard.2026.09.010

Gerald Chi, C Michael Gibson, Barry S Coller, Christopher B Granger, Gilles Montalescot, Sem A O F Rikken, Ashley Verburg, Jurrien M Ten Berg, Arnoud W J van 't Hof, James L Januzzi

{"title":"Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients With ST-Elevation Myocardial Infarction: Analysis From the CELEBRATE Trial.","authors":"Gerald Chi, C Michael Gibson, Barry S Coller, Christopher B Granger, Gilles Montalescot, Sem A O F Rikken, Ashley Verburg, Jurrien M Ten Berg, Arnoud W J van 't Hof, James L Januzzi","doi":"10.1016/j.amjcard.2026.09.010","DOIUrl":"10.1016/j.amjcard.2026.09.010","url":null,"abstract":"Renal impairment portends higher rates of clinical events and bleeding among patients with ST-segment elevation myocardial infarction (STEMI). Zalunfiban is a novel, subcutaneous glycoprotein IIb/IIIa inhibitor designed for prehospital administration. This post hoc analysis of the CELEBRATE trial evaluated the efficacy and safety of zalunfiban in STEMI patients across different levels of renal function. A total of 2,154 patients were categorized by baseline creatinine clearance (CrCl) levels. The primary efficacy endpoint was a 30-day major adverse composite clinical endpoint. The primary safety endpoint was Global Use of Strategies to Open Occluded Coronary Arteries severe or life-threatening bleeding at 30 days. Among patients with CrCl ≥ 30 to <60 ml/min, treatment with zalunfiban was associated with lower odds of the composite outcome (adjusted odds ratio 0.46, 95% confidence interval 0.23 to 0.94, p = 0.03). The treatment effect was not significantly modified by CrCl (p for interaction = 0.25). In addition, there were no significant differences in severe or life-threatening bleeding across all CrCl categories. Zalunfiban was associated with higher rates of mild-to-moderate bleeding among patients with CrCl ≥ 90 ml/min and those with ≥60 to <90 ml/min. A single subcutaneous dose of zalunfiban administered at first medical contact was not associated with an increased risk of major bleeding across the spectrum of renal function. In conclusion, although a signal for greater clinical benefit was observed among STEMI patients with CrCl ≥ 30 to <60 ml/min, there was no significant interaction by renal function, and these findings should be considered exploratory. A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI (CELEBRATE); ClinicalTrials.gov identifier: NCT04825743.","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

At the Edge of Failure: Predicting Hemodynamic Collapse 在失败的边缘：预测血液动力学崩溃。

IF 2.5 3区医学

American Journal of Cardiology Pub Date : 2026-07-15 Epub Date: 2026-05-17 DOI: 10.1016/j.amjcard.2026.05.006

Sanjay A Chandrasekhar MD, Mohamed Moussa MD, Amit Alam MD

引用次数: 0

Same-Day Discharge After Percutaneous Coronary Intervention for Chronic Total Occlusions: Patient’s Characteristics and Procedural Success Predict Timing of Hospital Leave and Outcome 慢性全闭塞经皮冠状动脉介入治疗后同日出院：患者特征和手术成功预测出院时间和结果

IF 2.1 3区医学

American Journal of Cardiology Pub Date : 2026-06-01 Epub Date: 2026-03-04 DOI: 10.1016/j.amjcard.2026.03.007

Gjin Ndrepepa MD

引用次数: 0